Emerald Advisers LLC Has $1.88 Million Stock Holdings in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD)

Emerald Advisers LLC cut its position in shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD - Free Report) by 41.9% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 456,770 shares of the biotechnology company's stock after selling 329,567 shares during the quarter. Emerald Advisers LLC owned 0.29% of Ironwood Pharmaceuticals worth $1,882,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. CWM LLC increased its holdings in shares of Ironwood Pharmaceuticals by 55.1% in the 2nd quarter. CWM LLC now owns 6,600 shares of the biotechnology company's stock valued at $43,000 after purchasing an additional 2,345 shares during the period. PNC Financial Services Group Inc. grew its position in Ironwood Pharmaceuticals by 152.2% during the fourth quarter. PNC Financial Services Group Inc. now owns 4,383 shares of the biotechnology company's stock valued at $50,000 after purchasing an additional 2,645 shares in the last quarter. Diversified Trust Co acquired a new position in Ironwood Pharmaceuticals in the 3rd quarter valued at approximately $52,000. Legacy Capital Group California Inc. purchased a new stake in Ironwood Pharmaceuticals in the 3rd quarter worth approximately $59,000. Finally, GAMMA Investing LLC boosted its stake in shares of Ironwood Pharmaceuticals by 344.1% during the 2nd quarter. GAMMA Investing LLC now owns 10,526 shares of the biotechnology company's stock valued at $69,000 after buying an additional 8,156 shares during the period.

Ironwood Pharmaceuticals Price Performance

NASDAQ:IRWD remained flat at $4.19 during midday trading on Monday. 1,146,623 shares of the company were exchanged, compared to its average volume of 2,965,169. The firm has a market capitalization of $669.31 million, a PE ratio of 104.00 and a beta of 0.47. Ironwood Pharmaceuticals, Inc. has a 1-year low of $3.79 and a 1-year high of $15.70. The business has a fifty day moving average price of $4.35 and a two-hundred day moving average price of $5.69.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on IRWD shares. Wells Fargo & Company cut their price objective on Ironwood Pharmaceuticals from $14.00 to $12.00 and set an "overweight" rating for the company in a report on Friday, August 9th. Leerink Partnrs raised Ironwood Pharmaceuticals to a "hold" rating in a research note on Monday, September 9th. Craig Hallum dropped their price objective on Ironwood Pharmaceuticals from $14.00 to $10.00 and set a "buy" rating on the stock in a report on Friday, August 9th. Capital One Financial cut shares of Ironwood Pharmaceuticals from an "overweight" rating to an "equal weight" rating and reduced their target price for the company from $12.00 to $4.00 in a research note on Thursday, August 8th. Finally, StockNews.com upgraded shares of Ironwood Pharmaceuticals from a "hold" rating to a "buy" rating in a research note on Tuesday, July 16th. Three investment analysts have rated the stock with a hold rating and five have given a buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $12.17.

Insider Transactions at Ironwood Pharmaceuticals

In related news, insider Minardo John sold 9,910 shares of the stock in a transaction that occurred on Monday, August 12th. The stock was sold at an average price of $4.27, for a total transaction of $42,315.70. Following the completion of the sale, the insider now owns 284,661 shares in the company, valued at $1,215,502.47. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 12.90% of the stock is currently owned by corporate insiders.

Ironwood Pharmaceuticals Profile

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.